On July 29, 2013, Depomed, Inc. (DEPO) announced that it had acquired the U.S. and Canadian rights to Lazanda nasal spray from Archimedes Pharma Limited. Lazanda, a transmucosal immediate-release fentanyl (TIRF) product, is indicated for the management of breakthrough pain in cancer patients (BTPc) 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Below we provide some background information on Depomed , Lazanda and the BTPc market, and why we believe the deal makes sense from a strategic standpoint for the company.
Depomed - A Pain Focused Specialty Pharma
Newark, California-based Depomed, Inc. is a specialty pharmaceutical company with a focus...
Only subscribers can access this article, which is part of the PRO research library covering 3,581 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: